David R. Margrave - 15 Jul 2024 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Chief Financial Officer
Signature
/s/ David R. Margrave
Issuer symbol
LTRN
Transactions as of
15 Jul 2024
Transactions value $
$0
Form type
4
Filing time
17 Jul 2024, 16:30:15 UTC
Previous filing
02 Nov 2021
Next filing
23 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Award $0 +52K $0.00 52K 15 Jul 2024 Common Stock 52K $4.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024.